Acurx Pharmaceuticals LLC

Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.

Earnings data Q1 2023

Earnings data Q2 2023

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q4 2022 Earnings Conference Call March 16, 2023 8:00 AM ET Company Participants Robert Shawah - Co-Founder & Chief Financial Officer David Luci - President & Chief Executive Officer Conference Call Participants Jason McCarthy - Maxim James Molloy - Alliance Global Partners Operator Greetings and welcome to the Acurx Pharmaceutical Fourth Quarter and Full Year 2022 Financial Results and Business Update. [Operator Instructions] As a reminder, this conference is being recorded.

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2022 Earnings Call Transcript

STATEN ISLAND, N.Y. , March 16, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the fourth quarter and full year ended December 31, 2022.

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

STATEN ISLAND, N.Y. , March 6, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its fourth quarter 2022 and fiscal year end 2022 financial results on Thursday, March 16, 2022, at 8:00 am ET before the U.S. financial markets open.

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update

Acurx Pharmaceuticals CEO David Luci tells Soulstring Media Group why he thinks his company and lead drug candidate, Ibezapolstat, can be a front-line treatment against C. difficileNew York, New York--(Newsfile Corp. - February 7, 2023) - Soulstring Media Group, Llc., a market research, aggregator, and digital media production and management company specializing in creating and syndicating content from publicly traded and private companies, announced today that it had published an in-depth interview with Acurx Pharmaceuticals (NASDAQ: ACXP) President and CEO, Mr. David Luci. The interview discusses ACXP's ongoing Phase 2b trial utilizing ibezapolstat to treat C.

CEO Spotlight: Acurx Pharmaceuticals CEO Confident His Phase 2b Ibezapolstat Drug Candidate Can Earn Front-Line Designation to Treat C. difficile

Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive question and answer session at the Emerging Growth Conference STATEN ISLAND, N.Y. , Jan. 16, 2023  /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, is pleased to announce that it has been invited to present at the Emerging Growth Conference on January 25, 2023.

Acurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023

Start Time: 08:30 January 1, 0000 8:49 AM ET Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q3 2022 Earnings Conference Call November 14, 2022, 08:30 AM ET Company Participants David Luci - President and CEO Robert Shawah - Co-Founder and CFO Conference Call Participants Jason McCarthy - Maxim Group Operator Greetings. Welcome to Acurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022.

Acurx Pharmaceuticals, Inc. (ACXP) Q3 2022 Earnings Call Transcript

STATEN ISLAND, N.Y. , Nov. 14, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the quarter ended September 30, 2022.

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2022 Results and Provides Business Update

STATEN ISLAND, N.Y. , Nov. 1, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2022 third quarter financial results on Monday, November 14, 2022, at 8:30 am ET before the U.S. financial markets open.

Acurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022 Conference Call and Provide Business Update

Presents research on ibezapolstat's selective activity on healthy bacteria within the gut microbiome in the treatment of C. difficile Infection (CDI) Emerging ibezapolstat microbiome data demonstrate that favorable effects seen in the Ph1 healthy volunteer study are also observed in the Ph2a trial in CDI patients treated with ibezapolstat Currently enrolling Ph2b trial in up to 30 U.S. sites will compare efficacy of ibezapolstat to vancomycin Ibezapolstat is FDA QIDP and Fast Track Designated for priority review STATEN ISLAND, N.Y.

Acurx Announces Scientific Oral and Poster Presented at IDWeek 2022

New emerging, favorable microbiome data to be presented from previously completed Ph1 healthy volunteers and Ph2a patients with C. difficile Infection clinical trials Extends research on ibezapolstat's selective activity compared to healthy bacteria within the gut microbiome in the treatment of CDI STATEN ISLAND, N.Y.

Acurx Announces Scientific Oral and Poster Presentations at IDWeek

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q2 2022 Earnings Conference Call August 16, 2022 8:30 AM ET Company Participants Robert Shawah - CFO David Luci - CEO Conference Call Participants Jim Molloy - Alliance Global Partners Operator Greetings. Welcome to Acurx Pharmaceuticals' Second Quarter 2022 Results and Business Update.

Acurx Pharmaceuticals, Inc. (ACXP) CEO David Luci on Q2 2022 Results - Earnings Call Transcript

STATEN ISLAND, N.Y. , Aug. 15, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the quarter ended June 30, 2022.

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2022 Results and Provides Business Update

STATEN ISLAND, N.Y. , Aug. 4, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2022 second quarter financial results on Tuesday, August 16, 2022, at 8:30 am ET before the U.S. financial markets open.

Acurx Pharmaceuticals, Inc. to Discuss 2022 Second Quarter Financial Results on August 16, 2022 Conference Call and Provide Business Update

New data link beneficial microbiome changes in Ph2a CDI patients to earlier results from Ph1 healthy volunteers to predict potential anti-recurrence properties of ibezapolstat New in vitro data show ibezapolstat is effective against high bacterial concentration (inoculum) of C. difficile) and does not induce production of C.

Acurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI at the 16th Biennial Congress of the Anaerobe Society of America

STATEN ISLAND, N.Y. , July 25, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into definitive agreements with a single healthcare-focused U.S. institutional investor and certain executives of the Company for the purchase and sale of an aggregate of 1,289,980 shares of its common stock (which includes 130,769 pre-funded warrants to purchase shares of its common stock being sold to the U.S. institutional investor) at a purchase price per share of $3.25 (or $3.2499 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant) for the U.S. institutional investor and $3.80 per share for the Company's executives, pursuant to a registered direct offering.

Acurx Pharmaceuticals, Inc. Announces $4.225 Million Registered Direct Offering

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Rob Shawah - Chief Financial Officer David Luci - President and Chief Executive Officer Conference Call Participants Chad Yahn - Maxim Group Joanne Lee - Maxim Group Operator Greetings and welcome to the Acurx Pharmaceuticals, Inc. First Quarter 2022 Results and Business Update. At this time, all participants are in a listen-only mode.

Acurx Pharmaceuticals, Inc.'s (ACXP) CEO David Luci on Q1 2022 Results - Earnings Call Transcript

STATEN ISLAND, N.Y. , May 11, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the quarter ended March 31, 2022.

Acurx Pharmaceuticals, Inc. Reports First Quarter 2022 Results and Provides Business Update

STATEN ISLAND, N.Y. , April 29, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2022 first quarter financial results on Wednesday, May 11 2022, at 8:30 am ET before the U.S. financial markets open.

Acurx Pharmaceuticals, Inc. to Discuss 2022 First Quarter Financial Results on May 11, 2022 Conference Call and Provide Business Update

Acurx Pharmaceuticals, Inc. (ACXP) CEO David Luci on Q4 2021 Results - Earnings Call Transcript

STATEN ISLAND, N.Y., March 17, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the fourth quarter and full year ended December 31, 2021.

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update

STATEN ISLAND, N.Y., March 16, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that Company's President & CEO, David P.

Acurx Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28-30, 2022 from 9:00 a.m. - 5:00 p.m.

STATEN ISLAND, N.Y., March 7, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its fourth quarter 2021 and fiscal year end 2021 financial results on Thursday, March 17, 2022, at 8:30 am ET before the U.S. financial markets open.

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update

STATEN ISLAND, N.Y., Feb. 7, 2022 /PRNewswire/ --  Publication of study presents: Clinical results of 10 of 10 patients (100%) enrolled met the study's primary and secondary efficacy endpoints of Clinical Cure at end of treatment and Sustained Clinical Cure of no recurrence of CDI at the 28-day follow-up visit PK data showing low plasma and high fecal concentrations of ibezapolstat Favorable microbiome changes included regrowth of Actinobacteria and Firmicutes phylum species while on treatment Potential beneficial effects on bile acid metabolism while on treatment Currently enrolling Ph2b trial in 12 U.S. sites will compare efficacy of ibezapolstat to vancomycin Ibezapolstat is FDA QIDP and Fast Track Designated for priority review Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that results of its positive Phase 2a clinical trial have been published in Clinical Infectious Diseases, the official publication of the Infectious Disease Society of America https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac096/6522822?login=true.

Acurx Announces Publication of Positive Phase 2a Clinical Trial Results of Ibezapolstat for CDI in Clinical Infectious Diseases

STATEN ISLAND, N.Y. , Dec. 6, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the first patient has been enrolled in its Phase 2b clinical trial of ibezapolstat, its lead antibiotic candidate, against the standard of care to treat CDI, vancomycin, in a 64 patient double-blind randomized trial expected to be completed mid-2022.

Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI)

Acurx Pharmaceuticals, Inc. (ACXP) CEO David Luci on Q3 2021 Earnings Call Transcript

News for Acurx Pharmaceuticals LLC Stock (ACXP)